Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.

A prognostic score model to determine which breast cancer patients with 1-3 positive lymph nodes after modified radical mastectomy should receive radiotherapy.

Chen D, Wang H, Song X, Shi F, Kong L, Yu J.

Oncotarget. 2017 Oct 5;9(1):385-393. doi: 10.18632/oncotarget.21531. eCollection 2018 Jan 2.

2.

Current Trends in Postmastectomy Breast Reconstruction.

Panchal H, Matros E.

Plast Reconstr Surg. 2017 Nov;140(5S Advances in Breast Reconstruction):7S-13S. doi: 10.1097/PRS.0000000000003941. Review.

PMID:
29064917
3.

Possible benefits from post-mastectomy radiotherapy in node-negative breast cancer patients: a multicenter analysis in Korea (KROG 14-22).

Park HJ, Shin KH, Kim JH, Ahn SD, Kim SS, Kim YB, Park W, Kim YJ, Shin HS, Kim JH, Lee SY, Kim K, Park KR, Jeong BK.

Oncotarget. 2017 Mar 15;8(35):59800-59809. doi: 10.18632/oncotarget.16241. eCollection 2017 Aug 29.

4.

Clinical significance of the lymph node ratio in N1 breast cancer.

Kim J, Kim JH, Kim OB, Oh YK, Park SG.

Radiat Oncol J. 2017 Sep;35(3):227-232. doi: 10.3857/roj.2017.00101. Epub 2017 Sep 15.

5.

Development of nomograms to predict axillary lymph node status in breast cancer patients.

Chen K, Liu J, Li S, Jacobs L.

BMC Cancer. 2017 Aug 23;17(1):561. doi: 10.1186/s12885-017-3535-7.

6.

Tissue expansion for breast reconstruction: Methods and techniques.

Bertozzi N, Pesce M, Santi P, Raposio E.

Ann Med Surg (Lond). 2017 Jul 21;21:34-44. doi: 10.1016/j.amsu.2017.07.048. eCollection 2017 Sep. Review.

7.

Post-operative radiotherapy is beneficial for T1/T2 triple negative breast cancer patients with four or more positive lymph nodes.

Chen L, Zhang J, Chen J, Liu L, Liang L, Shangguan Z, Wang D.

Oncotarget. 2017 Jun 27;8(26):42917-42925. doi: 10.18632/oncotarget.17170.

8.

Role of postmastectomy radiotherapy in early-stage (T1-2N0-1M0) triple-negative breast cancer: a systematic review.

Chen F, Pu F.

Onco Targets Ther. 2017 Apr 6;10:2009-2016. doi: 10.2147/OTT.S123803. eCollection 2017. Review.

9.

The value of FATS expression in predicting sensitivity to radiotherapy in breast cancer.

Zhang J, Wu N, Zhang T, Sun T, Su Y, Zhao J, Mu K, Jin Z, Gao M, Liu J, Gu L.

Oncotarget. 2017 Jun 13;8(24):38491-38500. doi: 10.18632/oncotarget.16630.

10.

Incorporating Risk Factors to Identify the Indication of Post-mastectomy Radiotherapy in N1 Breast Cancer Treated with Optimal Systemic Therapy: A Multicenter Analysis in Korea (KROG 14-23).

Park HJ, Shin KH, Kim JH, Ahn SD, Kim JY, Park W, Kim YB, Kim YJ, Kim JH, Kim K, Park KR, Shin HS, Jeong BK, Lee SY, Kim S.

Cancer Res Treat. 2017 Jul;49(3):739-747. doi: 10.4143/crt.2016.405. Epub 2016 Oct 19.

11.

Comparison of Treatment Outcomes between Breast Conserving Surgery Followed by Radiotherapy and Mastectomy Alone in Patients with T1-2 Stage and 1-3 Axillary Lymph Nodes in the Era of Modern Adjuvant Systemic Treatments.

Kim SW, Chun M, Han S, Jung YS, Choi JH, Kang SY, Jang H, Jo S.

PLoS One. 2016 Sep 29;11(9):e0163748. doi: 10.1371/journal.pone.0163748. eCollection 2016.

12.

Postmastectomy Radiation Therapy and Two-Stage Implant-Based Breast Reconstruction: Is There a Better Time to Irradiate?

Santosa KB, Chen X, Qi J, Ballard TN, Kim HM, Hamill JB, Bensenhaver JM, Pusic AL, Wilkins EG.

Plast Reconstr Surg. 2016 Oct;138(4):761-9. doi: 10.1097/PRS.0000000000002534.

13.

Postmastectomy Radiotherapy: An American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Focused Guideline Update.

Recht A, Comen EA, Fine RE, Fleming GF, Hardenbergh PH, Ho AY, Hudis CA, Hwang ES, Kirshner JJ, Morrow M, Salerno KE, Sledge GW Jr, Solin LJ, Spears PA, Whelan TJ, Somerfield MR, Edge SB.

Ann Surg Oncol. 2017 Jan;24(1):38-51. doi: 10.1245/s10434-016-5558-8. Epub 2016 Sep 19.

14.

Operation with less adjuvant therapy for elderly breast cancer.

Yamada A, Narui K, Sugae S, Shimizu D, Takabe K, Ichikawa Y, Ishikawa T, Endo I.

J Surg Res. 2016 Aug;204(2):410-417. doi: 10.1016/j.jss.2016.05.031. Epub 2016 May 26.

15.

Post-mastectomy radiation therapy without usage of a bolus may be a reasonable option.

Nakamura N, Arahira S, Zenda S, Yoneyama K, Mukai H, Onozawa M, Toshima M, Motegi A, Hirano Y, Hojo H, Kibe Y, Akimoto T.

J Radiat Res. 2017 Jan;58(1):66-70. doi: 10.1093/jrr/rrw055. Epub 2016 Jul 15.

16.

SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer.

Nahleh ZA, Barlow WE, Hayes DF, Schott AF, Gralow JR, Sikov WM, Perez EA, Chennuru S, Mirshahidi HR, Corso SW, Lew DL, Pusztai L, Livingston RB, Hortobagyi GN.

Breast Cancer Res Treat. 2016 Aug;158(3):485-95. doi: 10.1007/s10549-016-3889-6. Epub 2016 Jul 8.

17.

An Eighteen-Gene Classifier Predicts Locoregional Recurrence in Post-Mastectomy Breast Cancer Patients.

Cheng SH, Horng CF, Huang TT, Huang ES, Tsou MH, Shi LS, Yu BL, Chen CM, Huang AT.

EBioMedicine. 2016 Feb 16;5:74-81. doi: 10.1016/j.ebiom.2016.02.022. eCollection 2016 Mar.

18.

Evaluation of various boluses in dose distribution for electron therapy of the chest wall with an inward defect.

Mahdavi H, Jabbari K, Roayaei M.

J Med Phys. 2016 Jan-Mar;41(1):38-44. doi: 10.4103/0971-6203.177288.

19.

One-step nucleic acid amplification assay for intraoperative prediction of advanced axillary lymph node metastases in breast cancer patients with sentinel lymph node metastasis.

Kubota M, Komoike Y, Hamada M, Shinzaki W, Azumi T, Hashimoto Y, Imoto S, Takeyama Y, Okuno K.

Mol Clin Oncol. 2016 Feb;4(2):173-178. Epub 2015 Dec 7.

20.

Supplemental Content

Support Center